A Dark Vector Cognition product

Item 1. Financial Statements

44K characters. Original on sec.gov ·

Item 1. Financial Statements

The 26 tables in Item 1. Financial Statements as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Condensed Consol****idated Balance Sheets

$ in millions, except per share amounts (unaudited)

May 3, 2025February 1, 2025May 4, 2024
Assets
Current assets
Cash and cash equivalents$1,147$1,578$1,214
Receivables, net7441,044770
Merchandise inventories5,1945,0855,225
Other current assets500517544
Total current assets7,5858,2247,753
Property and equipment, net2,0892,1222,196
Operating lease assets2,8212,8332,771
Goodwill9089081,383
Other assets725695649
Total assets$14,128$14,782$14,752
Liabilities and equity
Current liabilities
Accounts payable$4,670$4,980$4,664
Unredeemed gift card liabilities246253242
Deferred revenue891951923
Accrued compensation and related expenses367464380
Accrued liabilities617741812
Current portion of operating lease liabilities611617613
Current portion of long-term debt101015
Total current liabilities7,4128,0167,649
Long-term operating lease liabilities2,2772,2822,222
Long-term debt1,1531,1441,134
Long-term liabilities523532665
Contingencies (Note 10)
Equity
Best Buy Co., Inc. Shareholders' Equity
Preferred stock, $1.00 par value: Authorized - 400,000 shares; Issued and outstanding - none---
Common stock, $0.10 par value: Authorized - 1.0 billion shares; Issued and outstanding - 211.3 million, 211.4 million and 216.1 million shares, respectively222222
Additional paid-in capital--26
Retained earnings2,4282,4862,722
Accumulated other comprehensive income313300312
Total equity2,7632,8083,082
Total liabilities and equity$14,128$14,782$14,752

NOTE: The Consolidated Balance Sheet as of February 1, 2025, has been condensed from the audited consolidated financial statements.

See Notes to Condensed Consolidated Financial Statements.

‎

Condensed Consolidated Statements of Earnings

$ and shares in millions, except per share amounts (unaudited)

Three Months Ended
May 3, 2025May 4, 2024
Revenue$8,767$8,847
Cost of sales6,7186,783
Gross profit2,0492,064
Selling, general and administrative expenses1,7211,737
Restructuring charges10915
Operating income219312
Other income (expense):
Investment income and other1525
Interest expense(12)(12)
Earnings before income tax expense and equity in income (loss) of affiliates222325
Income tax expense1980
Equity in income (loss) of affiliates(1)1
Net earnings$202$246
Basic earnings per share$0.95$1.14
Diluted earnings per share$0.95$1.13
Weighted-average common shares outstanding:
Basic212.0216.2
Diluted213.0217.2

See Notes to Condensed Consolidated Financial Statements.

‎

Conde****nsed Consolidated Statements of Comprehensive Income

$ in millions (unaudited)

Three Months Ended
May 3, 2025May 4, 2024
Net earnings$202$246
Foreign currency translation adjustments, net of tax13(5)
Comprehensive income$215$241

See Notes to Condensed Consolidated Financial Statements.

‎

Condens****ed Consolidated Statements of Cash Flows

$ in millions (unaudited)

Three Months Ended
May 3, 2025May 4, 2024
Operating activities
Net earnings$202$246
Adjustments to reconcile net earnings to total cash provided by operating activities:
Depreciation and amortization211219
Restructuring charges10915
Stock-based compensation4038
Deferred income taxes(51)14
Other, net(2)(2)
Changes in operating assets and liabilities:
Receivables298168
Merchandise inventories(95)(273)
Other assets7(8)
Accounts payable(330)43
Income taxes713
Other liabilities(362)(317)
Total cash provided by operating activities34156
Investing activities
Additions to property and equipment(166)(152)
Other, net-(15)
Total cash used in investing activities(166)(167)
Financing activities
Repurchase of common stock(100)(50)
Dividends paid(202)(202)
Other, net(3)-
Total cash used in financing activities(305)(252)
Effect of exchange rate changes on cash and cash equivalents4(3)
Decrease in cash, cash equivalents and restricted cash(433)(266)
Cash, cash equivalents and restricted cash at beginning of period1,8681,793
Cash, cash equivalents and restricted cash at end of period$1,435$1,527

See Notes to Condensed Consolidated Financial Statements.

‎

Condensed Consolidated Statements of Changes in Shareholders' Equity

$ and shares in millions, except per share amounts (unaudited)

Common SharesCommon StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive Income (Loss)Total
Balances at February 1, 2025211.4$22$-$2,486$300$2,808
Net earnings, three months ended May 3, 2025---202-202
Other comprehensive income:
Foreign currency translation adjustments, net of tax----1313
Stock-based compensation--40--40
Issuance of common stock1.5-2--2
Common stock dividends, $0.95 per share--6(208)-(202)
Repurchase of common stock(1.6)-(48)(52)-(100)
Balances at May 3, 2025211.3$22$-$2,428$313$2,763
Balances at February 3, 2024215.4$22$31$2,683$317$3,053
Net earnings, three months ended May 4, 2024---246-246
Other comprehensive loss:
Foreign currency translation adjustments, net of tax----(5)(5)
Stock-based compensation--38--38
Issuance of common stock1.4-4--4
Common stock dividends, $0.94 per share--5(207)-(202)
Repurchase of common stock(0.7)-(52)--(52)
Balances at May 4, 2024216.1$22$26$2,722$312$3,082

See Notes to Condensed Consolidated Financial Statements.

‎

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Basis of Presentation

Unless the context otherwise requires, the terms “Best Buy,” “we,” “us”, “our” and the “company” in these Notes to Condensed Consolidated Financial Statements refers to Best Buy Co., Inc. and, as applicable, its consolidated subsidiaries.

In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for a fair presentation as prescribed by accounting principles generally accepted in the U.S. (“GAAP”). All adjustments were comprised of normal recurring adjustments, except as noted in these Notes to Condensed Consolidated Financial Statements.

A large proportion of our revenue and earnings is generated in the fiscal fourth quarter, which includes the majority of the holiday shopping season. Due to the seasonal nature of our business, interim results are not necessarily indicative of results for the entire fiscal year. The interim financial statements and the related notes included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended February 1, 2025. The first three months of fiscal 2026 and fiscal 2025 each included 13 weeks.

In preparing the accompanying condensed consolidated financial statements, we evaluated the period from May 3, 2025, through the date the financial statements were issued for material subsequent events requiring recognition or disclosure. No such events were identified.

Recently Issued Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure of specific categories meeting a quantitative threshold within the income tax rate reconciliation, as well as disaggregation of income taxes paid by jurisdiction. This ASU, which can be applied either prospectively or retrospectively, is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of the ASU and expect to include updated income tax disclosures in our fiscal 2026 Form 10-K.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure of specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. We are currently evaluating the impact of the ASU and expect to include updated expense disclosures in our fiscal 2028 Form 10-K.

Supply Chain Financing

We have a supply chain financing program with an independent financial institution, whereby some of our suppliers have the opportunity to receive accounts payable settlements early, at a discount, facilitated by the financial institution. Our liability associated with the funded participation in the program, which is primarily included in Accounts payable on our Condensed Consolidated Balance Sheets, was $569 million, $398 million and $505 million as of May 3, 2025, February 1, 2025, and May 4, 2024, respectively.

Total Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash reported on our Condensed Consolidated Balance Sheets are reconciled to the total shown on our Condensed Consolidated Statements of Cash Flows as follows ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Cash and cash equivalents$1,147$1,578$1,214
Restricted cash included in Other current assets288290313
Total cash, cash equivalents and restricted cash$1,435$1,868$1,527

Amounts included in restricted cash are primarily restricted to cover product protection plans provided under our membership offerings and self-insurance liabilities.

Reclassification

Certain reclassifications of immaterial amounts previously reported have been made to the accompanying Condensed Consolidated Statements of Cash Flows to maintain consistency and comparability between periods presented.

2. Restructuring

Restructuring charges were as follows ($ in millions):

Three Months Ended
May 3, 2025May 4, 2024
Best Buy Health Optimization and China Sourcing Initiative$111$-
Fiscal 2024 Restructuring Initiative(2)16
Fiscal 2023 Resource Optimization Initiative-(1)
Total$109$15

Best Buy Health Optimization and China Sourcing Initiative

In the first quarter of fiscal 2026, we commenced a restructuring initiative primarily focused on optimizing our Best Buy Health business by taking actions to maximize value and improve profitability in light of its performance against our original forecasting. These actions include the decision to exit a component of the business within fiscal 2026. In addition, we also made significant changes to reduce our exposure to tariffs, particularly in China.

All charges incurred related to this initiative were from continuing operations in our Domestic segment and presented within Restructuring charges on our Condensed Consolidated Statements of Earnings. The composition of restructuring charges incurred related to this initiative were as follows ($ in millions):

Three Months Ended
May 3, 2025
Asset impairments and other costs(1)$73
Termination benefits38
Total$111

(1)Primarily represents the full impairment of net assets related to a component of our Best Buy Health business and other exit costs. The remaining carrying value of net assets approximates fair value and was immaterial as of May 3, 2025.

There were no cash payments related to this initiative during the first quarter of fiscal 2026 and our restructuring accrual liabilities as of May 3, 2025, were $66 million, reflecting expected future cash payments primarily during fiscal 2026. We currently do not expect to incur material future restructuring charges related to this initiative.

Fiscal 2024 Restructuring Initiative

During the fourth quarter of fiscal 2024, we commenced an enterprise-wide restructuring initiative intended to accomplish the following: (1) align field labor resources with where customers want to shop to optimize the customer experience; (2) redirect corporate resources for better alignment with our strategy; and (3) right-size resources to better align with our revenue outlook for fiscal 2025. We do not expect to incur material future restructuring charges related to this initiative.

All charges incurred related to this initiative were comprised of employee termination benefits from continuing operations and were presented within Restructuring charges on our Condensed Consolidated Statements of Earnings as follows ($ in millions):

Three Months EndedThree Months EndedCumulative Amount
May 3, 2025May 4, 2024As of May 3, 2025
Domestic$(2)$17$164
International-(1)8
Total$(2)$16$172

Restructuring accrual activity related to this initiative was as follows ($ in millions):

Termination Benefits
DomesticInternationalTotal
Balances at February 1, 2025$80$5$85
Cash payments(6)-(6)
Adjustments(1)(2)-(2)
Balances at May 3, 2025$72$5$77

(1)Represents adjustments primarily related to higher-than-expected employee retention from previously planned organizational changes.

3. Goodwill and Intangible Assets

Goodwill

Goodwill balances by segment were as follows ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Gross Carrying AmountCumulative ImpairmentGross Carrying AmountCumulative ImpairmentGross Carrying AmountCumulative Impairment
Domestic$1,450$(542)$1,450$(542)$1,450$(67)
International608(608)608(608)608(608)
Total$2,058$(1,150)$2,058$(1,150)$2,058$(675)

‎In fiscal 2025, we recorded a goodwill impairment of $475 million within the Domestic segment for the Best Buy Health reporting unit. The restructuring activity that commenced in the first quarter of fiscal 2026 was a triggering event to evaluate the Best Buy Health reporting unit for impairment. No further goodwill impairment was identified. Refer to Note 2, Restructuring, for additional information.

Definite-Lived Intangible Assets

We have definite-lived intangible assets recorded within Other assets on our Condensed Consolidated Balance Sheets as follows ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Gross Carrying‎Amount**(1)**Accumulated‎Amortization**(1)**Gross Carrying‎AmountAccumulated‎AmortizationGross Carrying‎AmountAccumulated‎AmortizationWeighted-Average Useful Life Remaining‎as of May 3, 2025 (in years)
Customer relationships$339$282$360$285$360$2788.2
Tradenames87769279108721.4
Developed technology565664616460-
Total$482$414$516$425$532$4107.1

(1)Gross carrying amount and accumulated amortization as of May 3, 2025, excludes $34 million and $16 million, respectively, of definite-lived intangible assets related to the exit of a component of our Best Buy Health business. See Note 2, Restructuring, for additional information.

Amortization expense was as follows ($ in millions):

Three Months Ended
Statement of Earnings LocationMay 3, 2025May 4, 2024
Amortization expenseSelling, general and administrative expenses$5$6

Amortization expense expected to be recognized in future periods is as follows ($ in millions):

Amortization Expense
Remainder of fiscal 2026$11
Fiscal 202713
Fiscal 20288
Fiscal 20297
Fiscal 20306
Fiscal 20315
Thereafter18

4**. Fair Value Measurements**

Fair value measurements are reported in one of three levels based on the lowest level of significant input used: Level 1 (unadjusted quoted prices in active markets); Level 2 (observable market inputs, other than quoted prices included in Level 1); and Level 3 (unobservable inputs that cannot be corroborated by observable market data).

Recurring Fair Value Measurements

Financial assets and liabilities accounted for at fair value were as follows ($ in millions):

Fair Value as of
Balance Sheet Location**(1)**Fair Value HierarchyMay 3, 2025February 1, 2025May 4, 2024
Assets
Money market funds(2)Cash and cash equivalentsLevel 1$79$439$234
Time deposits(3)Cash and cash equivalentsLevel 2232150110
Money market funds(2)Other current assetsLevel 1142140184
Time deposits(3)Other current assetsLevel 2505051
Marketable securities that fund deferred compensation(4)Other assetsLevel 1383949
Liabilities
Interest rate swap derivative instruments(5)Long-term liabilitiesLevel 281427

(1)Balance sheet location is determined by the length to maturity at date of purchase and whether the assets are restricted for particular use.

(2)Valued at quoted market prices in active markets at period end.

(3)Valued at face value plus accrued interest at period end, which approximates fair value.

(4)Valued using the performance of mutual funds that trade with sufficient frequency and volume to obtain pricing information on an ongoing basis.

(5)Valued using readily observable market inputs. These instruments are custom, over-the-counter contracts with various bank counterparties that are not traded on an active market. See Note 5, Derivative Instruments, for additional information.

Nonrecurring Fair Value Measurements

In the first quarter of fiscal 2026, we recorded asset impairments and other costs related to our Best Buy Health Optimization and China Sourcing Initiative. Refer to Note 2, Restructuring, for additional information.

Fair Value of Financial Instruments

The fair values of cash, certain restricted cash, receivables, accounts payable and other payables approximated their carrying values because of the short-term nature of these instruments. If these instruments were measured at fair value in the financial statements, they would be classified as Level 1 in the fair value hierarchy. Fair values for other investments held at cost are not readily available, but we estimate that the carrying values for these investments approximate their fair values.

Long-term debt is presented at carrying value on our Condensed Consolidated Balance Sheets. If our long-term debt were recorded at fair value, it would be classified as Level 2 in the fair value hierarchy. Long-term debt balances were as follows ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Fair ValueCarrying ValueFair ValueCarrying ValueFair ValueCarrying Value
Long-term debt(1)$1,043$1,142$1,031$1,136$994$1,123

(1)Excludes debt discounts, issuance costs and finance lease obligations.

5. Derivative Instruments

We manage our economic and transaction exposure to certain risks by using foreign exchange forward contracts to hedge against the effect of Canadian dollar exchange rate fluctuations on a portion of our net investment in our Canadian operations and by using interest rate swaps to mitigate interest rate risk on our $500 million of principal amount of notes due October 1, 2028. In addition, we use foreign currency forward contracts not designated as hedging instruments to manage the impact of fluctuations in foreign currency exchange rates relative to recognized receivable and payable balances denominated in non-functional currencies.

Our derivative instruments designated as net investment hedges and fair value hedges are recorded on our Condensed Consolidated Balance Sheets at fair value. The gross fair values of our outstanding derivative instruments and corresponding fair value classifications are included in Note 4, Fair Value Measurements.

‎

Notional amounts of our derivative instruments were as follows ($ in millions):

Contract TypeMay 3, 2025February 1, 2025May 4, 2024
Derivatives designated as net investment hedges$119$119$191
Derivatives designated as fair value hedges (interest rate swaps)500500500
No hedge designation (foreign exchange contracts)544257
Total$673$661$748

Effects of our derivative instruments on our Condensed Consolidated Statements of Earnings were as follows ($ in millions):

Gain (Loss) Recognized
Three Months Ended
Statement of Earnings LocationMay 3, 2025May 4, 2024
Interest rate swapsInterest expense$6$(15)
Adjustments to carrying value of long-term debtInterest expense(6)15
Total$-$-

6. Debt

Short-Term Debt

U.S. Revolving Credit Facility

On April 18, 2025, we entered into a $1.25 billion five-year senior unsecured revolving credit facility agreement (the “Five-Year Facility Agreement”) with a syndicate of banks. The Five-Year Facility Agreement replaced the previous $1.25 billion senior unsecured revolving credit facility (the “Previous Facility”) with a syndicate of banks, which was entered into April 2023 and scheduled to expire April 2028, but was terminated on April 18, 2025. The Five-Year Facility Agreement permits borrowings of up to $1.25 billion and expires in April 2030. There were no borrowings outstanding under the Five-Year Facility Agreement as of May 3, 2025, or the Previous Facility as of February 1, 2025, or May 4, 2024.

The interest rate under the Five-Year Facility Agreement is variable and is determined at our option as: (i) the sum of (a) the greatest of (1) U.S. Bank National Association’s prime rate, (2) the greater of the federal funds effective rate and the overnight bank funding rate plus, in each case, 0.5%, and (3) Adjusted Term Secured Overnight Financing Rate (the “Adjusted Term SOFR”) for an interest period of one month plus 1%, and (b) a variable margin rate (the “ABR Margin”); or (ii) Adjusted Term SOFR for the applicable interest period plus a variable margin rate (the “Term SOFR Margin”). In addition, a facility fee is assessed on the commitment amount. The ABR Margin, Term SOFR Margin and the facility fee are based upon our current senior unsecured debt rating. Under the Five-Year Facility Agreement, the ABR Margin ranges from 0.000% to 0.015%, the Term SOFR Margin ranges from 0.565% to 1.015%, and the facility fee ranges from 0.060% to 0.110%. The Five-Year Facility Agreement is guaranteed by certain of our subsidiaries and contains customary affirmative and negative covenants. Among other things, these covenants restrict our and certain of our subsidiaries’ abilities to incur liens on certain assets; make material changes in corporate structure or the nature of our business; dispose of material assets; engage in certain mergers, consolidations and certain other fundamental changes; or engage in certain transactions with affiliates.

The Five-Year Facility Agreement also contains a covenant that requires the registrant to maintain a maximum quarterly cash flow leverage ratio. The Five-Year Facility Agreement contains customary default provisions, including, but not limited to, failure to pay interest or principal when due and failure to comply with covenants.

Long-Term Debt

Long-term debt consisted of the following ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Notes, 4.45%, due October 1, 2028 ("2028 Notes")$500$500$500
Notes, 1.95%, due October 1, 2030 ("2030 Notes")650650650
Interest rate swap valuation adjustments(8)(14)(27)
Subtotal1,1421,1361,123
Debt discounts and issuance costs(6)(7)(8)
Finance lease obligations272534
Total long-term debt1,1631,1541,149
Less current portion101015
Total long-term debt, less current portion$1,153$1,144$1,134

Fair Value and Future Maturities

See Note 4, Fair Value Measurements, for the fair value of long-term debt. Both the 2028 Notes and the 2030 Notes mature within the next five fiscal years.

7. Revenue

We generate substantially all of our revenue from contracts with customers from the sale of products and services. Contract balances primarily relate to unfulfilled membership benefits and services not yet completed, product merchandise not yet delivered to customers, unredeemed gift cards and deferred revenue from our private label and co-branded credit card arrangement. Contract balances were as follows ($ in millions):

May 3, 2025February 1, 2025May 4, 2024
Receivables, net(1)$461$504$453
Short-term contract liabilities included in:
Unredeemed gift card liabilities246253242
Deferred revenue891951923
Accrued liabilities595057
Long-term contract liabilities included in:
Long-term liabilities221229239

(1)Receivables are recorded net of allowances for expected credit losses of $15 million, $20 million and $17 million as of May 3, 2025, February 1, 2025, and May 4, 2024, respectively.

During the first three months of fiscal 2026 and fiscal 2025, $614 million and $642 million of revenue was recognized, respectively, that was included in the contract liabilities at the beginning of the respective periods.

Estimated revenue from our contract liability balances expected to be recognized in future periods if the performance of the contract is expected to have an initial duration of more than one year is as follows ($ in millions):

Fiscal YearAmount
Remainder of fiscal 2026$24
Fiscal 202733
Fiscal 202829
Fiscal 202926
Fiscal 203026
Fiscal 203126
Thereafter89

See Note 11, Segments, for information on our revenue by reportable segment and product category.

8. Earnings per Share

We compute our basic earnings per share based on the weighted-average number of common shares outstanding and our diluted earnings per share based on the weighted-average number of common shares outstanding adjusted by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued as calculated using the treasury stock method.

Reconciliations of the numerators and denominators of basic and diluted earnings per share were as follows ($ and shares in millions, except per share amounts):

Three Months Ended
May 3, 2025May 4, 2024
Numerator
Net earnings$202$246
Denominator
Weighted-average common shares outstanding212.0216.2
Dilutive effect of stock compensation plan awards1.01.0
Weighted-average common shares outstanding, assuming dilution213.0217.2
Potential shares which were anti-dilutive and excluded from weighted-average share computations0.30.6
Basic earnings per share$0.95$1.14
Diluted earnings per share$0.95$1.13

9. Repurchase of Common Stock

On February 28, 2022, our Board of Directors approved a $5.0 billion share repurchase program. The program had $3.2 billion remaining available for repurchases as of May 3, 2025. There is no expiration date governing the period over which we can repurchase shares under this authorization.

Information regarding the shares we repurchased and retired was as follows ($ and shares in millions, except per share amounts):

Three Months Ended
May 3, 2025May 4, 2024
Total cost of shares repurchased$100$52
Average price per share$64.39$77.81
Number of shares repurchased and retired1.60.7

10. Contingencies

We are involved in a number of legal proceedings. Where appropriate, we have made accruals with respect to these matters, which are reflected on our Condensed Consolidated Financial Statements. However, there are cases where liability is not probable or the amount cannot be reasonably estimated and, therefore, accruals have not been made. We provide disclosure of matters where we believe it is reasonably possible the impact may be material to our Condensed Consolidated Financial Statements.

11. Segments

Segment and category revenue information was as follows ($ in millions):

Three Months Ended
May 3, 2025May 4, 2024
Domestic:
Computing and Mobile Phones$3,792$3,588
Consumer Electronics2,2372,364
Appliances1,0011,090
Entertainment449520
Services579578
Other6963
Total Domestic revenue$8,127$8,203
International:
Computing and Mobile Phones$324$318
Consumer Electronics173173
Appliances5760
Entertainment4246
Services3739
Other78
Total International revenue640644
Total revenue$8,767$8,847

‎

Adjusted operating income by segment and the reconciliation to consolidated earnings before income tax expense and equity in income (loss) of affiliates were as follows ($ in millions):

Three Months Ended
May 3, 2025May 4, 2024
Domestic (1)InternationalTotalDomestic (1)InternationalTotal
Revenue$8,127$640$8,767$8,203$644$8,847
Cost of sales6,2194996,7186,2864976,783
Adjusted SG&A (2)1,5791371,7161,5921391,731
Adjusted operating income$329$4$333$325$8$333
Restructuring charges10915
Intangible asset amortization56
Operating income219312
Other income (expense):
Investment income and other1525
Interest expense(12)(12)
Earnings before income tax expense and equity in income (loss) of affiliates$222$325

(1)Domestic segment adjusted operating income includes certain operations that are based in foreign tax jurisdictions and primarily relate to sourcing products into the U.S.

(2)Adjusted SG&A excludes amortization of definite-lived intangible assets associated with acquisitions.

Other information by segment was as follows ($ in millions):

Three Months Ended
May 3, 2025May 4, 2024
Assets
Domestic$12,835$13,483
International1,2931,269
Total assets$14,128$14,752
Capital expenditures
Domestic$150$138
International1614
Total capital expenditures$166$152
Depreciation and amortization
Domestic$201$209
International1010
Total depreciation and amortization$211$219

‎

Previous: Cover and table of contents · Next: Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations